Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Rilzabrutinib · Wayrilz, SAR444671

Small molecule · Inhibitor of Bruton's tyrosine kinase (BTK) · developed by Genzyme

Approved FDA, Aug 2025
SNY Developer
1 Registered trials

What is Rilzabrutinib?

Rilzabrutinib is an oral, covalent, reversible kinase inhibitor of Bruton's tyrosine kinase (BTK). It reduces B cell activation and autoantibody generation and blocks Fcγ receptor-mediated phagocytosis of antibody-coated cells. It is studied in immune thrombocytopenia and Graves' disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Wayrilz, SAR444671, PRN-1008
Drug type
Small molecule
Targets
Bruton's tyrosine kinase (BTK)
Mechanism
Inhibitor of Bruton's tyrosine kinase (BTK)
Pathways
B cell activation, Fcγ receptor-mediated phagocytosis of antibody-coated cells
Therapy area
Endocrine, Hematology, Immunology
Developer
Genzyme Corp (SNY)
FDA status
Approved as Wayrilz (August 29, 2025), NDA219685 · FDA label
UNII
NWN58M4F5T

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 26, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07216079 Phase 3 Immune Thrombocytopenia Active not recruiting SNY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Graves' DiseaseImmune Thrombocytopenia

Other drugs acting on BTK

More from Genzyme

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the SNY page.

Follow SNY, the company behind Rilzabrutinib

See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.